NASDAQ: MXCTMaxcyte Inc Stock Ownership - Who owns Maxcyte?
Insider buying vs selling
Have Maxcyte Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Douglas J. Swirsky | CHIEF FINANCIAL OFFICER | 2026-03-17 | 10,142 | $0.82 | $8.27kSell |
| Richard Douglas | Director | 2025-08-13 | 80,000 | $1.39 | $111.04kBuy |
| Stanley C. Erck | Director | 2025-08-13 | 100,000 | $1.37 | $137.20kBuy |
| William W. Brooke | Director | 2025-08-13 | 50,000 | $1.29 | $64.50kBuy |
| Maher Masoud | President and CEO | 2025-08-13 | 75,000 | $1.37 | $102.90kBuy |
| Douglas J. Swirsky | CHIEF FINANCIAL OFFICER | 2025-08-13 | 50,000 | $1.29 | $64.50kBuy |
| Rekha Hemrajani | Director | 2025-06-25 | 10,684 | $2.10 | $22.38kSell |
MXCT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when MXCT insiders and whales buy or sell their stock.
MXCT Shareholders
What type of owners hold Maxcyte Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Casdin Partners Master Fund LP | 9.34% | 10,000,000 | $11.20M | Insider |
| Blackrock Inc | 8.21% | 8,798,473 | $9.85M | Institution |
| Capricorn Fund Managers Ltd | 7.65% | 8,200,000 | $9.18M | Institution |
| Vitruvian Partners LLP | 4.71% | 5,043,356 | $5.65M | Institution |
| Vanguard Capital Management LLC | 3.72% | 3,981,816 | $4.46M | Institution |
| Morgan Stanley | 3.44% | 3,688,131 | $4.13M | Institution |
| Mudita Advisors LLP | 3.15% | 3,370,689 | $3.78M | Institution |
| Bnp Paribas Asset Management Holding Sa | 2.59% | 2,773,554 | $3.11M | Institution |
| Geode Capital Management LLC | 2.21% | 2,362,672 | $2.65M | Institution |
| State Street Corp | 2.05% | 2,193,470 | $2.46M | Institution |
MXCT vs Medical Device Stocks
Maxcyte Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.